News
May 13, 2020
RETEVMO™ (selpercatinib)
Onco360® has been selected by Eli Lilly to be a specialty pharmacy partner for RETEVMO™ (selpercatinib), a novel oral treatment for adult patients with (RET) fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) and metastatic RET fusion-positive thyroid cancer.
April 20, 2020
Tukysa™ (tucatinib)
Onco360®, has been selected by Seattle Genetics to be a specialty pharmacy partner for TUKYSA™ (tucatinib), a new oral treatment used in combination with capecitabine and trastuzumab for adult patients with HER2-positive metastatic breast cancer who have received one or more prior anti-HER2-based regimens in the metastatic setting.
April 13, 2020
Koselugo (selumetinib)
Onco360® has been selected by AstraZeneca to be a specialty pharmacy partner for KOSELUGO™ (selumetinib), a novel oral kinase inhibitor indicated for the treatment of pediatric patients aged two years and above, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas.
March 13, 2020
Covid-19 Update For Patients
In response to the current COVID-19 situation, we’ve examined all areas of our business and pharmacy operations at every Onco360 location across the country and have taken actions to ensure continued service to our patients and their caregivers.
March 6, 2020
Onco360 Safety Awareness
Onco360 is aware of the emergence of the new coronavirus (COVID-19) illness and is closely monitoring the situation and possible future impact.
January 24, 2020
Tazverik™ (tazemetostat)
Epizyme has chosen Onco360 as the exclusive partner for TAZVERIK™ (tazemetostat), a new oral treatment for adult and pediatric patients (aged 16 years and older) with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
August 16, 2019
Now Dispensing INREBIC®
Onco360 is privileged to be selected as a specialty pharmacy provider for INREBIC®.
July 30, 2019
Dispensing NUBEQA®
NUBEQA® is available now through Onco360 Oncology Specialty Pharmacy.